UA26855C2 - Фармацевтичhа композиція, яка регулює гематопоез - Google Patents

Фармацевтичhа композиція, яка регулює гематопоез

Info

Publication number
UA26855C2
UA26855C2 UA5010234A UA5010234A UA26855C2 UA 26855 C2 UA26855 C2 UA 26855C2 UA 5010234 A UA5010234 A UA 5010234A UA 5010234 A UA5010234 A UA 5010234A UA 26855 C2 UA26855 C2 UA 26855C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
regulating hematopoiesis
composition regulating
hematopoiesis
lyophilised
Prior art date
Application number
UA5010234A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Хайнріх Воог
Вернер Грубер
Ханс-Йорг Маркль
Фрітц Деммер
Original Assignee
Беріhгер Маhhхайм Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Беріhгер Маhhхайм Гмбх filed Critical Беріhгер Маhhхайм Гмбх
Publication of UA26855C2 publication Critical patent/UA26855C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
UA5010234A 1987-09-05 1988-09-05 Фармацевтичhа композиція, яка регулює гематопоез UA26855C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729863 DE3729863A1 (de) 1987-09-05 1987-09-05 Stabilisierte erythropoietin-lyophilisate

Publications (1)

Publication Number Publication Date
UA26855C2 true UA26855C2 (uk) 1999-12-29

Family

ID=6335375

Family Applications (2)

Application Number Title Priority Date Filing Date
UA5010234A UA26855C2 (uk) 1987-09-05 1988-09-05 Фармацевтичhа композиція, яка регулює гематопоез
UA4356379A UA26123A (uk) 1987-09-05 1988-09-05 Спосіб одержаhhя іh'єкційhої форми еритропоетиhу

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA4356379A UA26123A (uk) 1987-09-05 1988-09-05 Спосіб одержаhhя іh'єкційhої форми еритропоетиhу

Country Status (29)

Country Link
US (1) US4992419A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0306824B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0780782B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960009929B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1027224C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE77556T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU610636B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1330301C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS274681B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD273004A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3729863A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK174811B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2051806T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI93517C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005454T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK89495A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU202761B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE60310B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL87628A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (1) LV10178B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX12880A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO178687C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ225975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH25618A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL157944B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT88417B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2043118C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (2) UA26855C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA886528B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0582933A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EA002754B1 (ru) * 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
RU2152206C1 (ru) * 1997-05-22 2000-07-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Таблетированная форма рекомбинантного человеческого эритропоэтина для перорального применения и способ ее получения
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US6391633B1 (en) * 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
RU2128517C1 (ru) * 1998-07-20 1999-04-10 Колобков Сергей Леонидович Стабилизированный водный раствор эритропоэтина
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
PL203797B1 (pl) * 1999-04-09 2009-11-30 Ortho Mcneil Pharm Inc Kompozycje farmaceutyczne erytropoetyny
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
TWI245645B (en) 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
RU2182141C2 (ru) * 2000-03-20 2002-05-10 Братский государственный технический университет Композиция для изготовления легкобетонных изделий
WO2001087329A1 (en) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
RU2191594C1 (ru) * 2001-04-03 2002-10-27 Григорян Седа Суреновна Средство и способ повышения резистентности к инфекции
RU2192882C1 (ru) * 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
AU2004244920B2 (en) * 2003-06-10 2009-07-23 Lg Chem, Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
ZA200603396B (en) * 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
DE102004011663B4 (de) * 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US8802628B2 (en) * 2008-08-15 2014-08-12 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
JP2013501071A (ja) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ, インコーポレイテッド リナクロチドを含む処方物
WO2011056850A2 (en) * 2009-11-03 2011-05-12 Ironwood Pharmaceuticals, Inc. Treatment of chronic constipation
AU2011207916B2 (en) * 2010-01-19 2014-01-23 Hanmi Science Co., Ltd. Liquid formulations for long-acting erythropoietin conjugate
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
EA022327B1 (ru) * 2013-01-04 2015-12-30 Общество С Ограниченной Ответственностью "Рубикон" Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения
EP3125922B1 (en) 2014-03-29 2020-10-14 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of conjugated erythropoietin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3686684T2 (de) * 1985-03-06 1993-01-28 Survival Technology Mittel zur absorptionsverbesserung von proteinen.

Also Published As

Publication number Publication date
US4992419A (en) 1991-02-12
RU2100032C1 (ru) 1997-12-27
UA26123A (uk) 1999-06-07
DK483188D0 (da) 1988-08-30
IE60310B1 (en) 1994-06-29
FI884051A0 (fi) 1988-09-02
KR960009929B1 (ko) 1996-07-25
NO883926L (no) 1989-03-06
NO178687C (no) 1996-05-15
JPS6471818A (en) 1989-03-16
NO883926D0 (no) 1988-09-02
KR890004718A (ko) 1989-05-09
DK174811B1 (da) 2003-12-01
CA1330301C (en) 1994-06-21
CN1031801A (zh) 1989-03-22
DE3872334D1 (de) 1992-07-30
DD273004A5 (de) 1989-11-01
PT88417B (pt) 1992-10-30
NO178687B (no) 1996-02-05
HK89495A (en) 1995-06-16
PT88417A (pt) 1989-07-31
AU610636B2 (en) 1991-05-23
PL274485A1 (en) 1989-04-17
IL87628A (en) 1993-07-08
FI93517C (fi) 1995-04-25
CS274681B2 (en) 1991-09-15
ZA886528B (en) 1989-05-30
ATE77556T1 (de) 1992-07-15
CS590188A2 (en) 1990-12-13
HU202761B (en) 1991-04-29
LV10178B (en) 1995-04-20
MX12880A (es) 1993-12-01
EP0306824B1 (de) 1992-06-24
PH25618A (en) 1991-08-08
EP0306824A2 (de) 1989-03-15
ES2051806T3 (es) 1994-07-01
DE3729863A1 (de) 1989-03-16
RU2043118C1 (ru) 1995-09-10
NZ225975A (en) 1991-07-26
PL157944B1 (en) 1992-07-31
IE882671L (en) 1989-03-05
LV10178A (lv) 1994-10-20
DK483188A (da) 1989-03-06
IL87628A0 (en) 1989-01-31
EP0306824A3 (en) 1990-01-31
HUT47863A (en) 1989-04-28
CN1027224C (zh) 1995-01-04
FI884051L (fi) 1989-03-06
FI93517B (fi) 1995-01-13
AU2173988A (en) 1989-04-27
JPH0780782B2 (ja) 1995-08-30
GR3005454T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-24

Similar Documents

Publication Publication Date Title
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
EG18379A (en) Novel pharmacological compounds
GR3006518T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL74804A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
EP0232849A3 (en) Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
IL80659A (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
GR3006815T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
ZA91115B (en) Topical compositions
NZ217356A (en) Benzamide derivatives and pharmaceutical compositions
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
ZA913435B (en) Aqueous pharmaceutical formulations of erythropoietin and the use thereof
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
TR23253A (tr) Zorunlu olarak sodyum suelfat meydana gelmeden parafin-sulfoksidasyon-reaksiyon karisimlarindan alkali suelfat bakimindan fakir parafin suelfonot'larinin ve suelfuerik asidin izde edilmesine mahsus usul
FR2657258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE8703183L (sv) Nya galeniska beredningar
IL74760A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
JPS6429320A (en) Drug composition
ATE62593T1 (de) Physiologisch wirksame und naehrende zusammensetzung.
IT8420355A0 (it) Derivato del p-aminofenolo conattivita'mucosecretolitica-fluidificante e antipiretica, procedimento per lasua preparazione e sue composizioni farmaceutiche.